Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


PBAC evidence under pressure

Posted 15 October 2020

The PBAC needs "greater flexibility" to evaluate and fund the growing number of new health technologies heading to market, according to chair Professor Andrew Wilson - pointing to a potential shake up to the way the reimbursement body does business.

Addressing a 260-strong online audience at the ARCS virtual summit, Wilson spoke about real world evidence and its impact on clinical, regulatory and market access.  

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
How much to save the kid?
We paid a high price for our elderly so what about children
Special Report
Aust Covid Vaccine Tracker
UPDATES: Sanofi/GSK sign Statement of Intent with Gavi; Aust to import 3.8m vax doses
Approvals Action
Novartis' triplet inhaler ticked
First-in-class maintenance treatment of asthma